Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Increlex in PAPP-A2 Deficiency
NCT02636270Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Dec 2015
- Primary completion
- Oct 2022
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 2, open-label trial of mecasermin in short stature, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Height Velocity at 6 years. Started Dec 2015; status: completed.
02
Drugs
mecasermin
03
Conditions
short stature
Beyond the preview
Go deeper on NCT02636270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636270.